Trial Profile

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atabecestat (Primary) ; E 2814 (Primary) ; Florquinitau F18 (Primary) ; Gantenerumab (Primary) ; Lecanemab (Primary) ; Solanezumab (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Acronyms DIAN-TU; DIAN-TU-001; Tau NexGen Study

01 Apr 2025 Results assessing the safety and efficacy of multiple investigational products in participants with dominantly inherited Alzheimer's disease , published in the Lancet Neurology
03 Jul 2024 Planned End Date changed from 1 Oct 2027 to 1 Jul 2028.
03 Jul 2024 Planned primary completion date changed from 1 Oct 2027 to 1 Apr 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com